With a team of more than 20 specialists, the Fox Chase-Temple Urologic Institute has one of the largest urology programs in the region, making it a trusted regional leader in the treatment of urologic conditions.
The Fox Chase-Temple Urologic Institute will offer patients access to cutting-edge clinical trials, targeted therapies, immunotherapies, and advanced radiation therapies for the treatment of urologic cancers. Its urologic oncologists will collaborate closely with renowned medical and radiation oncologists to take a multidisciplinary approach to treating cancer, including diagnosis, treatment, and follow-up care.
Meeting biweekly to discuss patient cases and potential treatment options, the Institute’s team will leverage their extensive experience as one of the largest fellowship-trained genitourinary cancer teams in the country.
The Fox Chase-Temple Urologic Institute is designed to provide a seamless transition for patients with urologic cancers who require treatment for benign urology conditions following cancer therapy. These services as well as many others will be offered at multiple locations, including Temple University Hospital - Main Campus, Fox Chase Cancer Center – Main Campus, Fox Chase - East Norriton, Temple Health - Center City, Temple Health - Fort Washington, Fox Chase - Huntingdon Pike, and Chestnut Hill Hospital, with ongoing plans to add providers and expand in response to growth.
Dr kutikov
Dr. Cohn
Dr Uzzo
Dr. Lee
Dr. Alexander Kutikov, co-author of the studies and chief of the Division of Urology and Urologic Oncology at Fox Chase